Bristol Myers Squibb CO 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
Bristol-Myers Squibb reports flat 2025 revenues, with strong growth in its new portfolio offsetting declines from generic competition and increased government rebates.
NYSE
Bristol-Myers Squibb's 2024 results reflect revenue growth driven by key products and strategic acquisitions, offset by generic erosion and significant IPRD expenses.
NYSE
Bristol-Myers Squibb has granted restricted stock units to employees under its 2021 Stock Award and Incentive Plan, with vesting periods ranging from one to five years.